BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26238017)

  • 1. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
    Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
    Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
    Diaz ES; Walts AE; Karlan BY; Walsh CS
    Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
    Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
    Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.
    Aman M; Ohishi Y; Imamura H; Shinozaki T; Yasutake N; Kato K; Oda Y
    Hum Pathol; 2017 Jun; 64():156-163. PubMed ID: 28438620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
    Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
    Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival.
    Abu Saadeh F; Norris L; O'Toole S; Gleeson N
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):214-8. PubMed ID: 23830352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
    Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
    Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
    Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
    Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
    Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
    Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period.
    Zhou Q; Zhu C; Shen Z; Zhang T; Li M; Zhu J; Qin J; Xie Y; Zhang W; Chen R; Wang G; Qian L; Wu D; Nashan B; Zhou Y
    Eur J Surg Oncol; 2020 May; 46(5):855-861. PubMed ID: 32001042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
    Zhu J; Wen H; Bi R; Wu Y; Wu X
    J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
    Okoye E; Euscher ED; Malpica A
    Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
    Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
    J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
    Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
    Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study.
    Ye S; Yang J; Cao D; Bai H; Huang H; Wu M; Chen J; You Y; Lang J; Shen K
    PLoS One; 2015; 10(3):e0121818. PubMed ID: 25793293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
    Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
    Cohen JG; Prendergast E; Geddings JE; Walts AE; Agadjanian H; Hisada Y; Karlan BY; Mackman N; Walsh CS
    Gynecol Oncol; 2017 Jul; 146(1):146-152. PubMed ID: 28501328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.